Literature DB >> 3184352

Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS.

S Pahwa1, K Biron, W Lim, P Swenson, M H Kaplan, N Sadick, R Pahwa.   

Abstract

Acyclovir has become the treatment of choice for varicella-zoster virus (VZV) infections in immunocompromised individuals. This article describes a 4-year-old girl congenitally infected with human immunodeficiency virus who developed a continuous cutaneous infection with VZV that persisted over a 14-month period until her death. Initial episodes of varicella and zoster were responsive to acyclovir treatment; however, subsequent recurrences necessitated administration of multiple courses of acyclovir. Lesions became markedly hyperkeratotic, slow healing, and persistent despite acyclovir therapy. Numerous attempts to isolate virus from the lesions yielded only one isolate late in the course of therapy. This virus clearly demonstrated acyclovir resistance in vitro. Bizarre manifestations of VZV infection could present both diagnostic and therapeutic dilemmas. Prolonged acyclovir treatment of highly immunocompromised patients with acquired immunodeficiency syndrome and severe VZV may lead to the appearance of resistant virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3184352

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  24 in total

1.  Varicella zoster infection in HIV-infected children.

Authors:  C Rongkavilit; C D Mitchell; S Nachman
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

2.  Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine.

Authors:  T I Ng; Y Shi; H J Huffaker; W Kati; Y Liu; C M Chen; Z Lin; C Maring; W E Kohlbrenner; A Molla
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 3.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 4.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

5.  Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir.

Authors:  F Morfin; D Thouvenot; M De Turenne-Tessier; B Lina; M Aymard; T Ooka
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Differences in the Likelihood of Acyclovir Resistance-Associated Mutations in the Thymidine Kinase Genes of Herpes Simplex Virus 1 and Varicella-Zoster Virus.

Authors:  Hikaru Fujii; Shizuko Harada; Tomoki Yoshikawa; Souichi Yamada; Natsumi Omura; Miho Shibamura; Takuya Inagaki; Hirofumi Kato; Shuetsu Fukushi; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 7.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

8.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

Review 9.  Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus.

Authors:  J W Tappero; B A Perkins; J D Wenger; T G Berger
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

10.  Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.

Authors:  G B Roberts; J A Fyfe; R K Gaillard; S A Short
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.